Webinar tomorrow: Immunotherapy broad PBS listing case study
Webinar tomorrow: Immunotherapy broad PBS listing case study
The 1st March 2026 shift toward pan-tumour, multi-indication listings for immunotherapy represents a fundamental change in Australian medicine reimbursement. It signals a move away from the traditional, indication-by-indication submission process that has defined product lifecycle management for years.
For a full briefing on the policy shift, Minister Mark Butler’s recent announcement details the move toward clinician-led access for advanced cancers:
https://lnkd.in/gy7Ef4_D
Is this world-first broad listing a "unicorn" or the definitive way forward for the PBS? For pharmaceutical sponsors, the implications for market access and long-term commercial strategy are profound. Join tomorrow’s webinar, hosted by ISPOR Australia Chapter, to explore the mechanics of this shift and what it means for the future of oncology listings.
Strategic Considerations for Industry
For teams managing oncology portfolios, this raises a critical question: what other cancer immunotherapies in your pipeline can co-opt this emerging market access pathway? Understanding these criteria is now essential for any sponsor looking to streamline their Australian reimbursement trajectory.
Pulse Economics Consulting is pleased to support this ISPOR-AC initiative. Our Managing Director, Oona Reardon, will be chairing and facilitating the discussion.
Event Details
Date: Tomorrow, Tuesday 17 March
Time: 1:30pm – 2:00pm
Register: https://lnkd.in/gDi_8RwC
#HTA #PBS #MarketAccess #Immunotherapy #ISPOR #PulseEconomics #PharmaStrategy #Oncology